Overall, the SURPASS-AP-Combo trial is consistent with the results reported in previous SURPASS series trials, confirming the efficacy and safety of tsiparatide in the T2D population in the Asia-Pacific region, mainly Chinese patients
(PubMed) Contempre B, Dumont JE, Ngo B, Thilly CH, Diplock AT, Vanderpas J
With DACCaveats : Continuous GH exposure may cause receptor downregulation, leading to reduced effectiveness Side effects may occur, such as flushing, water retention, tingling, elevated blood pressure, headaches, and lethargy
For example, calcium in dairy products can bind to certain drugs in the stomach, forming a substance that the body cant absorb as easily
STRIDE is the only dedicated PAD functional outcomes trial with a GLP-1 RA